Related Experiment Videos
Cabergoline for levodopa-induced complications in Parkinson's disease
The Cochrane Database of Systematic Reviews
|May 2, 2001
Summary
Cabergoline may help reduce levodopa dosage in Parkinson's disease patients with motor complications. While not significantly reducing "off" time, it showed modest improvements in motor function and disability with an acceptable safety profile.
Area of Science:
- Neurology
- Pharmacology
Background:
- Long-term levodopa therapy for Parkinson's disease (PD) often leads to motor complications like involuntary movements and response fluctuations.
- Dopamine agonists are explored to mitigate these complications by reducing "off" periods and levodopa dependence.
Purpose of the Study:
- To evaluate the efficacy and safety of adding cabergoline to levodopa therapy in PD patients experiencing motor complications.
Main Methods:
- Systematic review of randomized controlled trials comparing cabergoline with placebo in PD patients on levodopa.
- Searches included MEDLINE, EMBASE, and the Cochrane Controlled Trials Register.
- Outcome measures comprised PD rating scales, levodopa dosage, "off" time, and adverse events.
Main Results:
- Three trials (268 patients) showed cabergoline significantly reduced levodopa dosage but did not significantly decrease "off" time.
- Modest improvements in some motor and disability scores were observed with cabergoline.
- A trend towards more dopaminergic adverse events and fewer withdrawals was noted with cabergoline, though not statistically significant.
Conclusions:
- Cabergoline can be utilized to decrease levodopa dosage and offer moderate improvements in motor function and disability in Parkinson's disease patients with motor complications.
- The evidence supporting these conclusions is primarily based on medium-term studies.